Pharmaceutical industry in the context of "Cleanroom"

Helminthiasis, also known as worm infection, is any macroparasitic disease of humans and other animals in which a part of the body is infected with parasitic worms, known as helminths. There are numerous species of these parasites, which are broadly classified into tapeworms, flukes, and roundworms. They often live in the gastrointestinal tract of their hosts, but they may also burrow into other organs, where they induce physiological damage.

Soil-transmitted helminthiasis and schistosomiasis are the most important helminthiases, and are among the neglected tropical diseases. These group of helminthiases have been targeted under the joint action of the world's leading pharmaceutical companies and non-governmental organizations through a project launched in 2012 called the London Declaration on Neglected Tropical Diseases, which aimed to control or eradicate certain neglected tropical diseases by 2020.

The chemical industry comprises the companies and other organizations that develop and produce industrial, specialty and other chemicals. Central to the modern world economy, the chemical industry converts raw materials (oil, natural gas, air, water, metals, and minerals) into commodity chemicals for industrial and consumer products. It includes industries for petrochemicals such as polymers for plastics and synthetic fibers; inorganic chemicals such as acids and alkalis; agricultural chemicals such as fertilizers, pesticides and herbicides; and other categories such as industrial gases, speciality chemicals and pharmaceuticals.

Various professionals are involved in the chemical industry including chemical engineers, chemists and lab technicians.

The London Declaration on Neglected Tropical Diseases was a collaborative disease eradication programme launched on 30 January 2012 in London. It was inspired by the World Health Organization roadmap to eradicate or prevent transmission for neglected tropical diseases by the year 2020. Officials from WHO, the World Bank, the Bill & Melinda Gates Foundation, the world's 13 leading pharmaceutical companies, and government representatives from US, UK, United Arab Emirates, Bangladesh, Brazil, Mozambique and Tanzania participated in a joint meeting at the Royal College of Physicians to launch this project. The meeting was spearheaded by Margaret Chan, Director-General of WHO, and Bill Gates, Co-Chair of the Bill & Melinda Gates Foundation.

This declaration was the largest coordinated effort to date in health issues and it aimed to eliminate or control 10 neglected diseases by 2020 by providing more than US$785 million to support research and development. These diseases are most rampant in economically deprived regions of the world and affect 1.4 billion people.

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research (506 total candidates in April 2021), with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

As early as March 2020, the World Health Organization (WHO), European Medicines Agency (EMA), US Food and Drug Administration (FDA), and the Chinese government and drug manufacturers were coordinating with academic and industry researchers to speed development of vaccines, antiviral drugs, and post-infection therapies. The International Clinical Trials Registry Platform of the WHO recorded 536 clinical studies to develop post-infection therapies for COVID-19 infections, with numerous established antiviral compounds for treating other infections under clinical research to be repurposed.

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products (EAEMP) or European Medicines Evaluation Agency (EMEA).

The EMA was set up in 1995, with funding from the European Union and the pharmaceutical industry, as well as indirect subsidy from member states, its stated intention to harmonise (but not replace) the work of existing national medicine regulatory bodies. The hope was that this plan would not only reduce the €350 million annual cost drug companies incurred by having to win separate approvals from each member state but also that it would eliminate the protectionist tendencies of sovereign states unwilling to approve new drugs that might compete with those already produced by domestic drug companies.

Specialty chemicals (also called specialties or effect chemicals) are particular chemical products that provide a wide variety of effects on which many other industry sectors rely. Some of the categories of speciality chemicals are adhesives, agrichemicals, cleaning materials, colors, cosmetic additives, construction chemicals, elastomers, flavors, food additives, fragrances, industrial gases, lubricants, paints, polymers, surfactants, and textile auxiliaries. Other industrial sectors such as automotive, aerospace, food, cosmetics, agriculture, manufacturing, and textiles are highly dependent on such products.

Speciality chemicals are materials used on the basis of their performance or function. Consequently, in addition to "effect" chemicals they are sometimes referred to as "performance" chemicals or "formulation" chemicals. They can be unique molecules or mixtures of molecules known as formulations. The physical and chemical characteristics of the single molecules or the formulated mixtures of molecules and the composition of the mixtures influences the performance end product. In commercial applications the companies providing these products more often than not provide targeted customer service to innovative individual technical solutions for their customers. This is a differentiating component of the service provided by speciality chemical producers when they are compared to the other sub-sectors of the chemical industry such as fine chemicals, commodity chemicals, petrochemicals and pharmaceuticals.

Medicine chest or medicine cabinet is a colloquial phrase and idiom used to describe an area with the highest concentration of medicine stockpile, production, or potential of sources for medicines. The phrase is used with the area to specify the scope, such as world's medicine chest or nation's medicine cabinet.